SubjectWell
SubjectWell is an Austin-based patient recruitment marketplace serving pharmaceutical sponsors, CROs, and clinical research sites globally, combining a 13M+ patient database, AI/ML matching, and a multilingual Patient Companion team across 36 countries to accelerate trial enrollment.
- Company typePrivate
- Founded2015
- HeadquartersAustin, United States
- Headcount101–250
- GTM typeB2B
- OfferingServices
What SubjectWell does
SubjectWell is an Austin, Texas-based patient recruitment and commercial solutions platform serving pharmaceutical sponsors, contract research organizations (CROs), clinical research sites, and brand marketers running clinical trials. The company's core offering is a marketplace-mediated recruitment service — Study Connect (tiered patient recruitment), Direct Connect (rapid marketplace-based patient matching), and Brand Connect (commercial-stage patient marketing) — combined with a globally distributed team of 100+ clinically trained, multilingual Patient Companions supporting patients in 36 countries across 22+ languages. At the center is the OneView recruitment portal, which centralizes referral management, integrates with sponsor and site CTMS systems via API, and applies AI/ML predictive models to match patients to trial criteria, forecast enrollment timelines, and quantify protocol burden through proprietary Site Burden Index and Patient Burden Index frameworks. The company reports a Patient Network of 13M+ patients (47% patients of color) with 300,000 added monthly, and claims 1,400+ studies completed, 15,500+ sites served, 500,000+ patient referrals delivered, and an average 30% reduction in enrollment timelines (≈6 months), with 48% of work involving rescue of trials already behind on enrollment.
SubjectWell's business model combines project-based professional services fees from pharma sponsors and CROs (the dominant stream) with subscription/recurring commercial revenue from Brand Connect and Treatment+ solutions targeting pharmaceutical brand marketers, medical device companies, and agencies. Go-to-market is sales-led, with dedicated Customer Success Managers and configurable tiered solutions; pricing is quote-based and not publicly disclosed. Geographically, the company operates as a remote-first organization with offices in Austin, Cape Town, and Munich, serving 102 countries.
The company's ownership history reflects a clear strategic trajectory: a $35M Series B in October 2022 (led by Asset Management Ventures with Bertelsmann), followed by acquisitions of PatientCentra (Nov 2023, rare disease/oncology) and Trials24 (Sep 2024, digital recruitment), a WindRose Health Investors take-private in April 2024, the OneView launch and SubjectWell 2.0 rebrand in February 2025, and a January 2026 merger with Clariness — backed by the same PE firm — to form a combined global full-service patient recruitment platform operating under the Clariness name, with 42,000+ cumulative randomizations across 400+ indications and 60+ country coverage. Fred Martin, the prior CEO, transitioned to a board role, and Jim Corrigan was appointed CEO of the merged entity.
SubjectWell firmographics
Firmographics- Name
- SubjectWell
- Legal name
- Subject Well, Inc.
- Website
- https://subjectwell.com
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- SubjectWell is an Austin-based patient recruitment marketplace serving pharmaceutical sponsors, CROs, and clinical research sites globally, combining a 13M+ patient database, AI/ML matching, and a multilingual Patient Companion team across 36 countries to accelerate trial enrollment.
- Ownership category
- akta.pro rank
SubjectWell industry classification
Industry- Product category
- Clinical Trial Patient Recruitment
- NAICS
- Scientific Research and Development Services (5417)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Site Identification & Feasibility (HLAGACAB)
- akta.pro secondary industry
- Clinical Trial Site Operations & Study Coordination (HLAGACAE)
Keywords
Where SubjectWell is headquartered
LocationHeadquarters
- HQ city
- Austin
- HQ country
- United States
- HQ region
- North America
Offices3 records
Markets served
SubjectWell business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure
Revenue model
- Patient Recruitment Services: Service contracts with pharmaceutical sponsors and CROs for patient recruitment solutions. Solutions include Study Connect (tiered patient recruitment), services (secondary screening, site support, translations), and technology platform access. Revenue generated through project-based fees or retainer arrangements with pharmaceutical companies conducting clinical trials.
- Brand Connect (Commercial Solutions): Commercial solutions for pharmaceutical brand marketers, medical device companies, and agencies to market products directly to condition-specific patient populations through SubjectWell's engaged Patient Network and extensive media network.
- Treatment+ Solutions: Commercial solutions connecting patients with new treatment and therapy options, reinforcing brand touchpoints with patients throughout their treatment journey to foster loyalty and strengthen patient-brand relationships.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Study Connect offers three flexible tiers to match clinical study needs |
Go-to-market motion1 record
Distribution channels3 records
Marketing channels8 records
SubjectWell product offering
Product offeringCore offering
SubjectWell is a risk-free clinical trials marketplace that recruits patients for pharmaceutical sponsors, CROs, and research sites. It combines the SubjectWell+ platform (OneView portal, AI/ML predictive matching, and a 13M+ Patient Network) with human Patient Companions to deliver Study Connect and Direct Connect recruitment solutions, plus Brand Connect for pharma commercial campaigns. Services span protocol feasibility, secondary screening, site support, and Full-Site Support across 102 countries.
Product overview
SubjectWell operates as a patient recruitment and commercial solutions platform organized around the SubjectWell+ platform architecture. The core portfolio consists of Study Connect (patient recruitment solution in three flexible tiers), Direct Connect (rapid patient recruitment through a marketplace model), and Brand Connect (commercial solutions for pharmaceutical marketing). The OneView Portal serves as the centralized technology platform providing recruitment oversight, real-time insights, and AI/ML-powered patient matching. The company maintains a Patient Network of 13M+ patients and provides complementary services including Patient Companions, Site Companions, Full-Site Support, Secondary Screening, and Virtual Waiting Room. SubjectWell supports recruitment across 102 countries with Patient Companions available in 36 countries speaking 22+ languages.
Differentiator
Problem solved
Functional benefit
Brands
- Study Connect: Patient recruitment solution available in three flexible tiers for clinical studies
- Direct Connect
- Brand Connect
- SubjectWell+ Platform
- OneView
- Patient Network
Products and services
- Study Connect Proven patient recruitment solution available in three flexible tiers that matches clinical study needs by combining SubjectWell technology, Patient Companions, creative expertise, and media network. Reduces enrollment time by 30% and produces quality referrals for US, global, and multi-country studies while minimizing site burden.
- Direct Connect Rapid patient recruitment solution leveraging SubjectWell's patient access marketplace to connect patients within study-appropriate geographies directly to study websites for registration and prescreening, using machine learning to match by condition and location.
- OneView Portal Centralized recruitment management platform that provides real-time insights for faster decision-making across all referral sources, sites, and studies. Integrates with existing systems such as CTMS, enhances workflow management, and uses AI/ML predictive models for targeted patient matching and personalized outreach strategies.
- Brand Connect Commercial solution enabling pharmaceutical brand marketers, medical device companies, and agencies to market healthcare products directly to condition-specific patient populations through SubjectWell's engaged Patient Network and media network, including Treatment+ Solutions for ongoing brand touchpoints.
- SubjectWell+ Platform Comprehensive technology platform that delivers patient recruitment and site enablement solutions, paired with advanced commercial capabilities to connect patients with clinical trials and new treatments. Combines the Patient Network database, OneView portal, AI/ML predictive models, and multi-channel engagement technology.
Quantifiable outcome
- 30% enrollment acceleration (average of 6 months reduction in recruitment time)
- +4 more outcomes
Companies that use SubjectWell
Customer profileNamed customers5 records
Segments5 records
Ideal customer profiles4 records
SubjectWell technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- Yes
- API docs
- API detail
Core technology
AI maturity
App detail
Integration1 record
AI capability6 records
Feature8 records
SubjectWell partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core and minor.
- ClarinesscoreSubjectWell merged with Clariness in January 2026 to form one of the largest global full-service patient recruitment platforms for clinical trials. The combined entity operates under the Clariness name, with support for clinical trials in over 60 countries, having delivered 42,000+ randomizations across 400+ indications and partnered with 10,000+ research sites globally. Transaction was led by WindRose Health Investors.
- Trials24coreSubjectWell acquired Trials24 in September 2024 to expand global patient engagement capabilities. The acquisition aims to enhance SubjectWell's reach, diversity, and technological offerings in clinical trial recruitment across multiple geographies.
- PatientCentracoreSubjectWell acquired PatientCentra in November 2023 to expand global patient recruitment capabilities, particularly for rare diseases and oncology research. PatientCentra brought 15 years of experience in digital patient recruitment across five continents, enabling end-to-end recruitment support for international clinical studies.
- Patient Advocacy GroupsminorPartnerships with patient advocacy organizations for rare disease awareness campaigns, community engagement, and patient education across various therapeutic areas.
- Healthcare ProvidersminorHealthcare provider networks and physician referral systems that direct patients toward clinical trial opportunities and support patient recruitment efforts.
- Media and Digital PartnersminorExtensive media network including retail pharmacies, labs, claims data providers, genomics companies, and digital health platforms that enable multi-channel patient outreach beyond traditional search and social.
Scale indicators16 records
Recent moves7 records
Expansion highlights6 records
SubjectWell competitors and assessment
Company assessmentDirect peers
- Antidote (Lumanity): Antidote, now part of Lumanity, is a patient recruitment marketplace connecting patients to clinical trials — directly competing with SubjectWell's core Direct Connect / Study Connect offerings across sponsors, CROs, and sites.
- Trialbee: Trialbee is a patient recruitment and engagement platform using data-driven targeting to match patients to trials. It competes head-to-head with SubjectWell's Study Connect and Direct Connect products across global sponsor and CRO accounts.
- Deep 6 AI: Deep 6 AI applies AI to electronic medical record data to accelerate patient identification and recruitment for clinical trials, competing with SubjectWell's AI/ML predictive matching and OneView platform.
Broad incumbents
- IQVIA: IQVIA is the world's largest CRO with embedded patient recruitment, real-world evidence, and clinical technology capabilities — a broad incumbent that competes with SubjectWell via bundled enterprise offerings.
- ICON plc: ICON is a top global CRO offering integrated patient recruitment and feasibility services to sponsors — a broad incumbent competing for the same enterprise trial recruitment budgets as SubjectWell.
- Parexel: Parexel is a major global CRO with patient recruitment, site services, and decentralized trial capabilities, competing with SubjectWell across large multi-country trials in oncology and rare disease.
- Medidata (Dassault Systèmes): Medidata provides clinical trial technology platforms (EDC, RTSM, eCOA) and increasingly patient-centric trial solutions — a broad incumbent competing with SubjectWell's technology layer for sponsor technology and data spend.
- Veeva Systems: Veeva provides clinical, regulatory, and quality software for life sciences, including Veeva Vault CTMS and eTMF. It competes with SubjectWell for sponsor technology spend and is increasingly adjacent to patient recruitment workflows.
Emerging players
- Curebase: Curebase is an emerging decentralized clinical trial platform with patient recruitment and virtual site capabilities — overlapping with SubjectWell's decentralized trial support and global recruitment ambitions.
Others
- WCG (WIRB-Copernicus Group): WCG provides clinical trial services including IRB review, site support, and patient engagement tools — an adjacent ecosystem participant whose site and sponsor relationships overlap with SubjectWell's customer base.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks7 records
Key highlights7 records
Customer concentration
SubjectWell social profiles
Digital presenceSubjectWell compliance and trust
Trust signalCompliance3 records
SubjectWell financial estimates
Financial estimateRevenue estimate
Valuation estimate
SubjectWell leadership team
Management profileNumber of profiles
Profiles15 records
SubjectWell subsidiaries and ownership
Company hierarchySubsidiaries2 records
SubjectWell funding detail
Funding detailFunding overview
Funding rounds6 records
Investors8 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
SubjectWell M&A and investment
M&A and investmentM&A2 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about SubjectWell
What does SubjectWell do?
SubjectWell is a risk-free clinical trials marketplace that recruits patients for pharmaceutical sponsors, CROs, and research sites. It combines the SubjectWell+ platform (OneView portal, AI/ML predictive matching, and a 13M+ Patient Network) with human Patient Companions to deliver Study Connect and Direct Connect recruitment solutions, plus Brand Connect for pharma commercial campaigns. Services span protocol feasibility, secondary screening, site support, and Full-Site Support across 102 countries.
Is SubjectWell a public or private company?
SubjectWell is a private company. It is classified as private equity controlled and is currently operating.
When was SubjectWell founded?
SubjectWell was founded in 2015. It employs 101 to 250 people.
Where is SubjectWell based?
SubjectWell is headquartered in Austin, United States, in the North America region.
How does SubjectWell make money?
Three revenue lines are on record. Patient Recruitment Services are the primary driver. The others are brand Connect (Commercial Solutions) and treatment+ Solutions.
Who are SubjectWell's main competitors?
Direct peers on record are Antidote (Lumanity), Trialbee and Deep 6 AI. Broad incumbents are IQVIA, ICON plc, Parexel, Medidata (Dassault Systèmes) and Veeva Systems. Curebase is listed as an emerging player. WCG (WIRB-Copernicus Group) is listed as an others.
Does SubjectWell have an API?
Yes. SubjectWell offers API integrations that enable CTMS and other system integrations to deliver referrals directly to customer systems. The API provides seamless access to referral data in a way that integrates best with customer workflows, eliminating time associated with fixing duplicate data entries and errors. Developer documentation is at client.subjectwell.com.
What industry is SubjectWell in?
SubjectWell's product category is Clinical Trial Patient Recruitment. Its primary akta.pro industry code is HLAGACAB, Site Identification & Feasibility, with a secondary code of HLAGACAE, Clinical Trial Site Operations & Study Coordination. Its NAICS code is 5417 and its SIC code is 8731.